6851858
Last Update Posted: 2025-05-13
Recruiting
All Genders accepted | 18 Years-75 Years |
64 Estimated Participants | No Expanded Access |
Interventional Study | Accepts healthy volunteers |
Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor Agonist
This Phase II study is a randomized, parallel group, double blinded, placebo-controlled, multicenter to evaluate the efficacy, safety, and tolerability of AZD6234 in adults with overweight or obesity and type 2 diabetes on stable GLP-1 RA therapy.
Eligibility
Relevant conditions:
Endocrinology
Diabetes, Type II
Obesity
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the trial if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov